Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
119.33
Oct 30 • 3:59 PM ET Dollar change+2.41 Percentage change(2.06%)
Aftermarket Close
120.04
Aftermarket • 7:59 PM ET Dollar change+0.71 Percentage change(0.59%)
Category
Global or ExUS Equities - Industry Sector
Sponsor
Van Eck Associates Corporation
Fund Family
Index
MVIS US Listed Pharmaceutical 25 Index
Index Weighting
Active/Passive
Expense
0.36%
Inverse/Leveraged
IPO
Dec 21, 2011
Asset Type
Equities (Stocks)
ETF Type
Bond Type
Average Maturity
Commodity Type
Quant Type
ESG Type
Dividend Type
Structure Type
Growth/Value
Market Cap
Option/Short
Yes / Yes
Tags
Tags
Tags
Tags
Tags
-
Tags
-
Tags
-
Sector/Theme
Region
SMA20
5.47%
SMA50
5.99%
SMA200
10.58%
Return% 1Y
33.85%
Return% 3Y
17.69%
Return% 5Y
12.01%
Return% 10Y
Return% SI
Flows% 1M
-2.04%
Flows% 3M
9.46%
Flows% YTD
-22.22%
Flows% 1Y
Flows% 3Y
Flows% 5Y
Trades
Total Holdings
26
AUM
1.10B
NAV/sh
52W High
118.03 1.10%
52W Low
91.04 31.07%
Volatility
1.56% 1.51%
ATR (14)
2.15
RSI (14)
68.01
Beta
0.45
Rel Volume
4.16
Avg Volume
306.78K
Volume
1,277,386
Perf Week
3.83%
Perf Month
10.35%
Perf Quarter
9.85%
Perf Half Y
16.62%
Perf YTD
15.66%
Perf Year
29.21%
Perf 3Y
58.58%
Perf 5Y
58.79%
Perf 10Y
127.56%
Prev Close
116.92
Price
119.33
Change %
2.06%
VanEck Pharmaceutical ETF seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.